Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / PTM Microarray: Request for Year 3 Set-Aside Funds

PTM Microarray: Request for Year 3 Set-Aside Funds

233
Post-translation modification for nitro-tyrosine and lipid peroxidation adducts on proteins secreted by the breast.
Case/control
Proteomics
Breast and Gynecologic Cancers Research

We hypothesize that PTMs on proteins that are secreted by the breast will provide a more sensitive method for detecting breast cancer than analysis of the parent protein. We will antibody microarrays to have examine 9 circulating proteins, each of which is known to be actively secreted by the breast, for several structurally and functionally distinct PTMs. We will determine if these modified proteins have the potential to used in the early detection of breast cancer.

Aim 1) Develop antibody microarray chips that can be used to measure PTMs associated with glycosylation state or nTyr- or HNE-adducts. This chip will target abundant proteins we have identified in NAF that are also found in the circulation. Aim 2) Evaluate two sets of human plasma samples from women with and without breast cancer using the chips developed in Aim 1. The first set of samples is from the Clinical Breast Care Program (CBCP, samples collected at Walter Reed Army Medical Center) and contains 80 samples from control women or women with DCIS or stage 1 or 2 breast cancer. This set of samples will determine if these assays can detect early disease. The second set of samples will be from Dr. Jeff Marks (Duke University) and will contain 60 samples evenly split between three study groups: control women and women with Her2+/ER- tumor, and women with ER+/Her2- breast cancer. This set of samples will determine if these assays can detect both early- and late-stage disease as well as differentiate between different subtypes of cancer.
ELISA microarray

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html